ANGLE PLC
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1994-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.angleplc.com
Clinical Trials
4
Trial Phases
0 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System
- Conditions
- Castration-resistant Prostate CancerProstate CancerHigh Risk Prostate CarcinomaBiochemically Recurrent Prostate Carcinoma
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- Angle plc
- Target Recruit Count
- 9
- Registration Number
- NCT05437679
- Locations
- 🇺🇸
MidLantic Urology, Pottstown, Pennsylvania, United States
Harvest of CTCs From MBC Patients Using the Parsortix™ PC1 System
- Conditions
- Healthy VolunteersBreast Cancer, Metastatic
- First Posted Date
- 2018-02-09
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Angle plc
- Target Recruit Count
- 421
- Registration Number
- NCT03427450
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸University of Rochester Medical Center Wilmot Cancer Institute, Rochester, New York, United States
Evaluation of Multiple Biomarkers to Estimate Risk of Ovarian Cancer in Patients With a Pelvic Mass.
- Conditions
- Ovarian Neoplasms
- First Posted Date
- 2016-05-30
- Last Posted Date
- 2018-11-09
- Lead Sponsor
- Angle plc
- Target Recruit Count
- 204
- Registration Number
- NCT02785731
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
🇩🇪Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany
🇩🇪Vivantes-Klinikum Neukölln, Berlin, Germany
Evaluation of Multiple Protein and Molecular Biomarkers to Estimate Risk of Cancer in Gynecology Patients Presenting With a Pelvic Mass.
- Conditions
- Ovarian Neoplasms
- First Posted Date
- 2016-05-24
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Angle plc
- Target Recruit Count
- 200
- Registration Number
- NCT02781272
- Locations
- 🇺🇸
University of Rochester Medical Center Wilmot Cancer Institute, Rochester, New York, United States
News
ANGLE's Parsortix System Enables Breakthrough Cancer Research Revealing CTC Clusters as Key Metastatic Drivers
ANGLE's Parsortix system has enabled multiple breakthrough studies published in high-impact journals, revealing novel insights into circulating tumor cell biology and cancer metastasis mechanisms.
ANGLE's Parsortix System Shows Promise in Real-Time HER2 Status Monitoring for Breast Cancer Patients
ANGLE plc has successfully completed development of two assays for AstraZeneca: an Androgen Receptor assay for prostate cancer and a DNA damage response micronuclei assay, positioning the company for large-scale clinical trials.
Digoxin Reduces Circulating Tumor Cell Cluster Size in Metastatic Breast Cancer
A clinical trial demonstrated that digoxin, a cardiac drug, significantly reduced the size of circulating tumor cell (CTC) clusters in metastatic breast cancer patients.